Mathilde Pauls

Mathilde Pauls

Auto-generated profile, based on publicly available information

Mathilde Pauls

Molecular & Clinical Sciences Research Institute St George's University of London London UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
MPMathilde M.H. Pauls
Mathilde M.H. Pauls
LBLauren R. Binnie
Lauren R. Binnie
PBPhilip Benjamin
Philip Benjamin
SBShai Betteridge
Shai Betteridge
BCBrian Clarke
Brian Clarke
AHAtticus H. Hainsworth
Atticus H. Hainsworth
Introduction: There are few randomized clinical trials in vascular cognitive impairment (VCI). This trial tested the hypothesis that the PDE5 inhibitor tadalafil, a widely used vasodilator, increases cerebral blood flow (CBF) in older people with symptomatic small vessel disease, the main cause of VCI.Methods: In a double‐blind, placebo‐controlled, cross‐over trial, participants received tadalafil (20 mg) and placebo on two visits ≥7 days apart (randomized to order of treatment). The primary endpoint, change in subcortical CBF, was measured by arterial spin labelling.Results: Tadalafil increased CBF non‐significantly in all subcortical areas (N = 55, age: 66.8 (8.6) years) with greatest treatment effect within white matter hyperintensities (+9.8%, P = .0960). There were incidental treatment effects on systolic and diastolic blood pressure (–7.8, –4.9 mmHg; P < .001). No serious adverse events were observed.Discussion: This trial did not identify a significant treatment effect of single‐administration tadalafil on subcortical CBF. To detect treatment effects may require different dosing regimens.

19 December 2017 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
MPMathilde Mh Pauls
Mathilde Mh Pauls
BMBarry Moynihan
Barry Moynihan
TBThomas Richard Barrick
Thomas Richard Barrick
CKChristina Kruuse
Christina Kruuse
JMJeremy B Madigan
Jeremy B Madigan
JIJeremy D Isaacs
Jeremy D Isaacs
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced. Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database (registration number CRD42016029668).

22 May 2017 in Trials
Verified
Journal Article
Open access
PDF file
MPMathilde M. H. Pauls
Mathilde M. H. Pauls
NCNatasha Clarke
Natasha Clarke
STSarah Trippier
Sarah Trippier
SBShai Betteridge
Shai Betteridge
FHFranklyn Howe
Franklyn Howe
AHAtticus H. Hainsworth
Atticus H. Hainsworth
Cerebral small vessel disease is a common cause of vascular cognitive impairment in older people, with no licensed treatment. Cerebral blood flow is reduced in small vessel disease. Tadalafil is a widely prescribed phosphodiesterase-5 inhibitor that increases blood flow in other vascular territories. The aim of this trial is to test the hypothesis that tadalafil increases cerebral blood flow in older people with small vessel disease. Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS) is a phase II randomised double-blind crossover trial. In two visits, 7-30 days apart, participants undergo arterial spin labelling to measure cerebral blood flow and a battery of cognitive tests, pre- and post-dosing with oral tadalafil (20 mg) or placebo. Sample size: 54 participants are required to detect a 15% increase in cerebral blood flow in subcortical white matter (p < 0.05, 90% power). Primary outcomes are cerebral blood flow in subcortical white matter and deep grey nuclei. Secondary outcomes are cortical grey matter cerebral blood flow and performance on cognitive tests (reaction time, information processing speed, digit span forwards and backwards, semantic fluency). Recruitment started on 4th September 2015 and 36 participants have completed to date (19th April 2017). No serious adverse events have occurred. All participants have been recruited from one centre, St George’s University Hospitals NHS Foundation Trust. European Union Clinical Trials Register: EudraCT number 2015-001235-20 . Registered on 13 May 2015.

13 April 2021 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
MPMathilde Pauls
Mathilde Pauls
MSMantegh Singh
Mantegh Singh
PMPeter Martin
Peter Martin
A 73-year-old man presented with unsteadiness and general malaise and later had problems with cognition. This was initially diagnosed as benign paroxysmal positional vertigo, but he was later found to have giant cell arteritis. Neurologists and physicians should be aware that giant cell arteritis can present with encephalopathy rather than the more typical features of headache, jaw pain and visual disturbance.

1 January 2022 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
MNMitsuko Nakajima
Mitsuko Nakajima
MPMathilde Pauls
Mathilde Pauls
SRSanjeev Rajakulendran
Sanjeev Rajakulendran
Nakajima M, et al. J Clin Neurol. 2022 Jan;18(1):105-107. https://doi.org/10.3988/jcn.2022.18.1.105